Absci Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Absci heeft een totaal eigen vermogen van $221.5M en een totale schuld van $6.2M, wat de schuld-eigenvermogensverhouding op 2.8% brengt. De totale activa en totale passiva bedragen respectievelijk $255.5M en $34.0M.

Belangrijke informatie

2.8%

Verhouding schuld/eigen vermogen

US$6.25m

Schuld

Rente dekkingsratio	n/a
Contant	US$145.25m
Aandelen	US$221.49m
Totaal verplichtingen	US$34.04m
Totaal activa	US$255.53m

Recente financiële gezondheidsupdates

Is Absci (NASDAQ:ABSI) A Risky Investment?

Jun 17

Recent updates

Absci: Embryonic Pipeline Looks Expensive Relative To Peers

Oct 29

Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile

Oct 03

Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships

Jul 28

Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out

Jan 10

IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)

Jul 22

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $165.2M ) ABSI } overtreffen de korte termijn passiva ( $25.5M ).

Langlopende schulden: De kortetermijnactiva ABSI ( $165.2M ) overtreffen de langetermijnschulden ( $8.6M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: ABSI heeft meer geld in kas dan de totale schuld.

Schuld verminderen: Er zijn onvoldoende gegevens om te bepalen of de schuld/eigen vermogen-ratio van ABSI de afgelopen 5 jaar is gedaald.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: ABSI heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: ABSI heeft voldoende kasruimte voor 1.4 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 17.2 % per jaar.

Absci Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Absci (NASDAQ:ABSI) A Risky Investment?

Recent updates

Absci: Embryonic Pipeline Looks Expensive Relative To Peers

Absci Corporation to Report Q3, 2024 Results on Nov 12, 2024

Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships

Absci Corporation to Report Q2, 2024 Results on Aug 14, 2024

Is Absci (NASDAQ:ABSI) A Risky Investment?

Chief Business Officer & CFO notifies of intention to sell stock

Chief Business Officer & CFO notifies of intention to sell stock

Consensus revenue estimates decrease by 26%

Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Absci Corporation to Report Q1, 2024 Results on May 14, 2024

Consensus revenue estimates fall by 20%

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates decrease by 13%

New minor risk - Shareholder dilution

Absci Corporation has filed a Follow-on Equity Offering in the amount of $75 million.

Absci Corporation has filed a Follow-on Equity Offering in the amount of $75 million.

Absci: Differentiated Antibody Discovery Play

Absci Initiates IND-Enabling Studies for Abs-101, A Potential Best-In-Class Anti-Tl1a Antibody De Novo Designed and Optimized Using Generative Ai

Absci Corporation to Present Preclinical Data for ABS-101, A Potential Best-In-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference

Absci Corporation Appoints Menelas Pangalos as Class II Director and Member of Compensation Committee of the Board, Effective January 1, 2024

Price target decreased by 14% to US$5.76

Consensus revenue estimates decrease by 42%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 15% to US$5.50

Consensus EPS estimates fall by 21%, revenue upgraded

Absci Corporation Announces Resignation of Sarah Korman as Chief Legal Officer and Interim Chief Business Officer, Effective as of September 15, 2023

Absci Corporation Appoints Zach Jonasson as Chief Business Officer, Effective from August 31, 2023

Absci Corporation Reports Impairment Results for the Second Quarter Ended June 30, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Absci Corporation and California Institute of Technology Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development

New major risk - Share price stability

Absci Corporation Appoints Frans Van Houten to Its Board of Directors

Price target decreased by 10% to US$7.73

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Casdin Capital Engages in Discussions with Absci Corporation

Price target decreased by 28% to US$8.60

Consensus revenue estimates decrease by 23%, EPS upgraded

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Casdin Capital Engages in Discussions with Absci Corporation

Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation

Absci Corporation Announces Ability to Create and Validate de novo Antibodies in Silico with Use of Zero-Shot Generative AI

Consensus forecasts updated

Price target decreased to US$12.10

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Absci Corporation Appoints Dan Rabinovitsj as Newest Member of its Board of Directors

Chief Financial Officer exercised options to buy US$155k worth of stock.

Absci Corporation Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer

Absci Corporation Announces End of Nikhil Goel as Chief Strategy Officer

Price target decreased to US$13.10

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Absci GAAP EPS of -$0.32 misses by $0.01, revenue of $1M misses by $0.68M

Eli Casdin Resigns from Board of Directors of Absci Corporation

Absci teams up to help develop antibody drugs for cancer

Absci Corporation(NasdaqGS:ABSI) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Consensus EPS estimates fall by 29%

Consensus revenue estimates fall by 17%

Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out

High number of new and inexperienced directors

Third quarter 2021 earnings released: US$0.33 loss per share

Absci, CORP has completed an IPO in the amount of $200 million.

IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven